Professional
Added to YB: 2025-05-07
Pitch date: 2025-03-31
VRTX [neutral]
Vertex Pharmaceuticals Incorporated
-7.04%
current return
Author Info
No bio for this author
Company Info
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Market Cap
$108.3B
Pitch Price
$486.27
Price Target
N/A
Dividend
N/A
EV/EBITDA
20.02
P/E
30.01
EV/Sales
8.37
Sector
Biotechnology
Category
growth
Baron Health Care Fund Portfolio Holding: Vertex Pharmaceuticals Incorporated
VRTX (holding update): Bullish on cystic fibrosis core + evolving pipeline. Journvax (non-opioid pain drug) launching despite Dec disappointment in lumbar spinal radiculopathy. High unmet need once payer criteria finalized. Pipeline strength in pain (multiple NaV inhibitors) and kidney (inaxaplin, povetacicept).
Read full article (1 min)